Evidence map›Paper›PMID 42038284›Full record

ArticleFrontiers in pharmacology2026

Oral 18-methoxycoronaridine activity in simian and murine

J C Delorenzi, T S Melo, F T Silveira, L A Carneiro, M B Campos, M R Cunha, E L Ricci, A R Fukushima, S L Hurst, S M Freeman and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

J C Delorenzi *Laboratory of Applied Pharmacology and Toxicology, Center of Biological and Health Sciences, Mackenzie Presbyterian University, SãoPaulo, Brazil.
T S MeloLaboratory of Applied Pharmacology and Toxicology, Center of Biological and Health Sciences, Mackenzie Presbyterian University, SãoPaulo, Brazil.
F T Silveira *Evandro Chagas Institute (Secretariat for Health and Environmental Surveillance, Ministry of Health), Ananindeua, Brazil.
L A CarneiroNational Primate Center, Ministry of Health, Ananindeua, PA, Brazil.
M B CamposEvandro Chagas Institute (Secretariat for Health and Environmental Surveillance, Ministry of Health), Ananindeua, Brazil.
M R CunhaDepartment of Organic Chemistry and Center of Medicinal Chemistry (CQMED), Center for Molecular Biology and Genetic Engineering (CBMEG), University of Campinas, UNICAMP, SP, Brazil.
E L RicciLaboratory of Applied Pharmacology and Toxicology, Center of Biological and Health Sciences, Mackenzie Presbyterian University, SãoPaulo, Brazil.
A R FukushimaDepartment of Pathology, Faculty of Veterinary Medicine and Animal Sciences, University of São Paulo, SãoPaulo, Brazil.
S L HurstMindMedicine, InC, New York, NY, United States.
S M FreemanMindMedicine, InC, New York, NY, United States.
M S Almeida-SaavedraLaboratory of Applied Pharmacology and Toxicology, Center of Biological and Health Sciences, Mackenzie Presbyterian University, SãoPaulo, Brazil.
A M MouradLaboratory of Applied Pharmacology and Toxicology, Center of Biological and Health Sciences, Mackenzie Presbyterian University, SãoPaulo, Brazil.
C Sacchelli-RamosLaboratory of Applied Pharmacology and Toxicology, Center of Biological and Health Sciences, Mackenzie Presbyterian University, SãoPaulo, Brazil.
L B O DelorenziLaboratory of Applied Pharmacology and Toxicology, Center of Biological and Health Sciences, Mackenzie Presbyterian University, SãoPaulo, Brazil.
G B DelorenziLaboratory of Applied Pharmacology and Toxicology, Center of Biological and Health Sciences, Mackenzie Presbyterian University, SãoPaulo, Brazil.
E M Saraiva *Laboratory of Innate Immunity, Department of Immunology, Paulo de Góes Microbiology Institute, Universidade Federal do Rio de Janeiro (UFRJ), Rio deJaneiro, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Leishmaniasis remains a major unmet medical need, with limited oral options and persistent constraints related to efficacy, tolerability, and treatment duration. We investigated 18-methoxycoronaridine (18-MC), an iboga-type indole alkaloid, as an oral candidate against Methods: Antileishmanial activity was first assessed in BALB/c mice treated orally with 18-MC (20 mg/kg/day). Translational efficacy was evaluated in non-human primates receiving oral 18-MC at 30 or 90 mg/kg/day for 28 days. Safety was characterized through acute and repeated-dose toxicology to establish the no-observed-adverse-effect level (NOAEL), complemented by pharmacokinetic analyses. Results: A 5-day oral regimen of 18-MC reduced murine tissue parasite burden (expressed as viable parasites per whole organ) by >99%. In Discussion: 18-MC demonstrates potent orally bioavailable antileishmanial activity with rodent-primate translational concordance and a safety profile compatible with first-in-human evaluation, supporting Phase I advancement with an estimated human equivalent dose of ∼16 mg/kg/day.

Indexed as

18-methoxycoronaridinechlorocebus aethiopscutaneous leishmaniasisleishmania amazonensisMacaca fascicularismurine experimental modelsoral treatmentsimian experimental models

Identifiers

PMID42038284
PMCPMC13106002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.